



Europäisches  
Patentamt  
European  
Patent Office  
Office européen  
des brevets

## SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:  
EP 22 90 07 22

### Classification of the application (IPC):

C07K 7/64, C07K 1/04, A61K 38/08, A61P 35/00, A61P 29/00, A61P 9/10,  
A61P 17/02, C07D 401/12, A61K 38/00, A61K 51/04

### Technical fields searched (IPC):

C07K, A61P, C07D, A61K

### DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim |
|----------|--|-------------------|
| A        | <p><b>ZHAO LIANG ET AL:</b> "Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review" <i>THERANOSTICS</i><br/>AU<br/>09 January 2022 (2022-01-09), vol. 12, no. 4, DOI: 10.7150/thno.69475,<br/>ISSN: 1838-7640, pages 1557-1569, XP093073430<br/>* the whole document *<br/>* figure 5; table 2 *</p>  | 1-11              |
| A        | <p><b>VAN DER HEIDE CIRCE D. ET AL:</b> "Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine" <i>EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING</i><br/>Berlin/Heidelberg<br/>05 July 2022 (2022-07-05), vol. 49, no. 13, DOI: 10.1007/s00259-022-05870-1, ISSN: 1619-7070, pages 4616-4641, XP093073435<br/>* the whole document *<br/>* page 4626 - page 4267; table 2 *</p> | 1-11              |
| A        | <p><b>GABRIEL FISCHER ET AL:</b> "Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant Diseases" <i>CHEMMEDCHEM COMMUNICATIONS, WILEY-VCH, DE</i>, 05 April 2013 (2013-04-05), vol. 8, no. 6, DOI: 10.1002/CMDC.201300081, ISSN: 1860-7179, pages 883-890, XP072422113<br/>* the whole document *<br/>* figures 4-5 *</p>   | 1-11              |
| A        | <p><b>LIU ZHAOFEI ET AL:</b> "Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using 18 F-labeled PEGylated RGD-Bombesin Heterodimer 18 F-FB-PEG 3 -Glu-RGD-BBN" <i>JOURNAL OF MEDICINAL CHEMISTRY</i><br/>US<br/>22 January 2009 (2009-01-22), vol. 52, no. 2, DOI: 10.1021/jm801285t, ISSN: 0022-2623, pages 425-432, XP093073438<br/>* the whole document *<br/>* figure 1 *</p>   | 1-11              |

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

|                           |  |                         |
|---------------------------|--|-------------------------|
| Place of search<br>Munich | Date of completion of the search<br>14 August 2023 | Examiner<br>Cervigni, S |
|---------------------------|--|-------------------------|

### CATEGORY OF CITED DOCUMENTS

- |   |  |
|---|--|
| X: particularly relevant if taken alone   | P: intermediate document   |
| Y: particularly relevant if combined with another document of the same category | T: theory or principle underlying the invention                        |
| A: technological background   | E: earlier patent document, but published on, or after the filing date |
| O: non-written disclosure   | D: document cited in the application                                   |
| & : member of the same patent family, corresponding document                    | L: document cited for other reasons                                    |

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



## SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:  
EP 22 90 07 22

### DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim |
|----------|--|-------------------|
| A        | <p><b>HU KONGZHEN ET AL:</b> "Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging"<br/> <b>PHARMACEUTICALS</b><br/> <b>CH</b><br/>           21 March 2022 (2022-03-21), vol. 15, DOI: 10.3390/ph15030383, ISSN: 1424-8247, pages 1-14, 383, XP093073439<br/>           * the whole document *<br/>           * figure 1 *</p> | 1-11              |

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

|                           |  |                         |
|---------------------------|--|-------------------------|
| Place of search<br>Munich | Date of completion of the search<br>14 August 2023 | Examiner<br>Cervigni, S |
|---------------------------|--|-------------------------|

### CATEGORY OF CITED DOCUMENTS

|   |  |
|---|--|
| X: particularly relevant if taken alone   | P: intermediate document   |
| Y: particularly relevant if combined with another document of the same category | T: theory or principle underlying the invention                        |
| A: technological background   | E: earlier patent document, but published on, or after the filing date |
| O: non-written disclosure   | D: document cited in the application                                   |
| & : member of the same patent family, corresponding document                    | L: document cited for other reasons                                    |

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.